title: Surfactant lavage with lidocaine improves pulmonary function in piglets after HCl-induced acute lung injury.
abstract: Acute respiratory distress syndrome (ARDS) is associated with significant morbidity and mortality. The pathophysiology of ARDS includes abnormalities of surfactant function as well as pulmonary inflammation. Immunomodulating drugs, like Lidocaine, have shown some success in decreasing inflammation in ARDS. We attempted to combine surfactant lavage's ability to reverse the surfactant dysfunction, while acting as a vehicle to deliver Lidocaine. Gravity-driven surfactant (Infasurf) lavage (35 ml/kg) was administered alone or mixed with Lidocaine after severe HCl acid injury (0.3 N; 3 cc/kg) in neonatal piglets. Treatment groups included: control (C) ( n = 5), surfactant lavage (SL) (35 ml/kg-diluted Infasurf) ( n = 7) and SL mixed with Lidocaine (SL+L) ( n = 7). About 26-27% of the lavage was retained (phospholipid 73-74 mg/kg; Lidocaine 1.8 mg/kg). Oxygenation progressively increased in the SL and SL+L groups over the 4-hour period (at 240 min: C = 99 +/- 14; SL = 154 +/- 39; SL+L = 230 +/- 40 mmHg) ( p < 0.05). PaCO(2) increased in all groups from 43 +/- 0.3 to 55 +/- 0.7 mmHg. Only SL+L showed a reduction in PaCO(2) (at 240 min: C = 54 +/- 4; SL = 53 +/- 7; SL+L = 49 +/- 2 mmHg) ( p < 0.05). Finally, SL and SL + L had superior characteristics during the quasi-static pressure volume (PV) procedure as compared to Control ( p < 0.05). In our HCl ALI model, SL improved oxygenation and quasi-static lung compliance over C. The pulmonary function effects of SL were further enhanced by the addition of Lidocaine to the surfactant suspension. Combining therapeutic agents with surfactant lavage may be an effective strategy in ALI.
authors.affiliation: Department of Clinical Investigation, Tripler Army Medical Center, TAMC, Honolulu, Hawaii 96826, USA.
authors.forename: T K
authors.initials: TK
authors.lastname: Huang
authors.forename: C F T
authors.initials: CF
authors.lastname: Uyehara
authors.forename: V
authors.initials: V
authors.lastname: Balaraman
authors.forename: C Y
authors.initials: CY
authors.lastname: Miyasato
authors.forename: D
authors.initials: D
authors.lastname: Person
authors.forename: E
authors.initials: E
authors.lastname: Egan
authors.forename: D
authors.initials: D
authors.lastname: Easa
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000818:Animals; D018893:Bronchoalveolar Lavage / Q000379:methods*; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination; D005260:Female; D006851:Hydrochloric Acid; D008012:Lidocaine / Q000008:administration & dosage*; D008168:Lung / Q000187:drug effects* / Q000502:physiology; D008297:Male; D011663:Pulmonary Surfactants / Q000008:administration & dosage*; D012016:Reference Values; D012128:Respiratory Distress Syndrome / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D012129:Respiratory Function Tests; D013500:Surface Tension / Q000187:drug effects; D013552:Swine
chemical_list: D000276:Adjuvants, Immunologic; D011663:Pulmonary Surfactants; D008012:Lidocaine; D006851:Hydrochloric Acid